H. Feuersenger

发表

Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema.

William H. Yang, J. Bernstein, H. Farkas, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters

P. Keith, T. Machnig, T. Craig, 2020, Thrombosis and Haemostasis.

Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.

T. Machnig, H. Farkas, J. Edelman, 2016, Annals of Allergy, Asthma & Immunology.

Predictive value of B-type natriuretic peptide levels in patients with paroxysmal and persistent atrial fibrillation undergoing pulmonary vein isolation

S. Degener, M. Horlitz, F. Krummenauer, 2011, Journal of Interventional Cardiac Electrophysiology.

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema

T. Machnig, J. Bernstein, W. Lumry, 2017, Allergy & rhinology.

Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.

T. Machnig, J. Bernstein, T. Craig, 2015, Allergy and asthma proceedings.

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema

I. Hussain, M. Cicardi, I. Pragst, 2018, Pediatric allergy, immunology, and pulmonology.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

William H. Yang, P. Keith, P. Kralickova, 2017, The New England journal of medicine.

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

J. Bernstein, T. Craig, M. Cicardi, 2015, Allergy.

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

H. Farkas, M. Cicardi, I. Pragst, 2020, Allergy, Asthma & Clinical Immunology.

Abstracts from the 10th C1-inhibitor deficiency workshop

William H. Yang, A. Szilágyi, M. Margaglione, 2017, Allergy, Asthma & Clinical Immunology.

Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data.

J. Bernstein, W. Lumry, P. Busse, 2016, The journal of allergy and clinical immunology. In practice.

Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients.

J. Bernstein, W. Lumry, P. Busse, 2017, The journal of allergy and clinical immunology. In practice.

A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

Dipti K. Pawaskar, C. Panousis, H. Feuersenger, 2021, Clinical and translational science.

Efficacy of C1-Inhibitor Concentrate (Berinert®) for the Treatment of Cutaneous Attacks of Acute Hereditary Angioedema Compared to Historical Untreated Controls

T. Machnig, J. Bernstein, T. Craig, 2013 .

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Pharmacokinetic Profile of Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) in Adolescent and Adult Patients with Hereditary Angioedema (HAE)

I. Pragst, Dipti K. Pawaskar, I. Jacobs, 2018, Pediatrics.

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

William H. Yang, J. Bernstein, W. Lumry, 2023, The Lancet.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

William H. Yang, P. Keith, W. Lumry, 2022, The Lancet.

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

T. Machnig, J. Bernstein, W. Lumry, 2019, Allergy, Asthma & Clinical Immunology.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

T. Machnig, J. Bernstein, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

LONG-TERM EFFICACY AND SAFETY OF SUBCUTANEOUS C1-INHIBITOR IN ELDERLY PATIENTS WITH HEREDITARY ANGIOEDEMA TYPE I/II

J. Bernstein, I. Pragst, J. Chiao, 2018, Annals of Allergy, Asthma & Immunology.

Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry.

J. Bernstein, W. Lumry, P. Busse, 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

W. Lumry, H. Farkas, T. Craig, 2017 .

Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.

I. Pragst, J. Dang, H. Feuersenger, 2022, Allergy and asthma proceedings.

Table of Contents

E. Aygören‐Pürsün, R. Brás, H. Feuersenger, 2020, Annals of Allergy, Asthma & Immunology.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.

W. Lumry, E. Aygören‐Pürsün, A. Reshef, 2024, The Lancet. Haematology.

University of Southern Denmark Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema

William H. Yang, H. Farkas, I. Pragst, 2020 .

Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.

T. Machnig, H. Farkas, J. Edelman, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.